杨艳梅,史克倩.泊沙康唑预防造血干细胞移植患者侵袭性真菌病临床观察[J].内科急危重症杂志,2016,22(5):
扫码阅读全文
|
| DOI： |
| 中文关键词: 泊沙康唑 侵袭性真菌病 预防 造血干细胞移植 |
| 英文关键词:posaconazole invasive fungal disease prevent hematopoietic stem cell transplantation. |
| 基金项目: |
|
| 摘要点击次数: 2553 |
| 全文下载次数: 3645 |
| 中文摘要: |
| 目的 观察泊沙康唑预防恶性血液病患者造血干细胞移植(HSCT)后侵袭性真菌病的临床效果和安全性。方法 收集我院血液科2015年3月-2016年2月HSCT 19例,2例移植前有肺部真菌病史,从预处理开始口服泊沙康唑600mg/天,至中性粒细胞恢复,之后异基因造血干细胞移植患者改为伊曲康唑或伏立康唑口服至 75天。结果 19例患者未发生突破性真菌感染,在泊沙康唑使用过程中未观察到严重毒副反应发生,到随访结束时,17例存活。结论 泊沙康唑对预防恶性血液病患者造血干细胞移植后侵袭性真菌病是安全、有效的。 |
| 英文摘要: |
| Abstrac Objective To observe the efficiency and safety of posaconazole on prevention invasive fungal disease in patients with hematopoietic stem cell transplantation （HSCT）. Methods From March 2015 -2016 February ,19patients who receiveed posaconazole prevented invasive fungal disease in the first people's Hospital of Yunnan Province after HSCT were analyzed retrospectively,2patients were pulmonary fungal disease before HSCT, posaconazole 600mg/day were to be taken orally beganning from pretreatment,to neutrophil recovery,afterward， itraconazole or voriconazole were to be taken orally to 75 days in patients with allogeneic hematopoietic stem cell transplantation. Results No breakthrough fungal infection occurred in 19 patients,no serious side effects were observed during the use of posaconazole, finally 17 patients survival. Conclusion Posaconazole prevented invasive fungal disease after hematopoietic stem cell transplantation is safty and effective. |
|
|
|
|
